Literature DB >> 25332555

Concomitant Myeloproliferative and Lymphoid Neoplasms in Two Patients Positive for JAK2 V617F Mutation. Case Report and Literature Review.

Adrian P Trifa1, Andrei Cucuianu2, Radu A Popp1, Mariana Paţiu2, Cristina Selicean2, Mariela S Militaru1, Ioan V Pop1.   

Abstract

The coexistence of both myeloproliferative and lymphoproliferative neoplasms in the same patient is an uncommon finding. We report two patients who presented such an association. The first patient was initially diagnosed with essential thrombocythemia, developing a clinical and haematological picture consistent with chronic lymphocytic leukaemia several years afterwards. The second patient was diagnosed concomitantly with polycythaemia vera and chronic lymphocytic leukaemia. Both patients were positive for the JAK2 V617F mutation. In the first patient the chronic lymphocytic leukaemia was asymptomatic, stage A, and did not require any additional treatment, while the second patient presented with generalized large lymphadenopathy (stage B) and chronic lymphocytic leukaemia-related symptoms, requiring chronic lymphocytic leukaemia-directed treatment. It is unclear whether there is a pathogenetic link between the myeloproliferative and lymphoproliferative diseases encountered in these patients, both being probably the result of random mutations occurring in distinct initiating cells. However, given the higher risk of lymphoproliferative neoplasms development in myeloproliferative neoplasms patients reported in larger studies, the genomic instability characteristic to myeloproliferative neoplasms may play a role in subsequent lymphoproliferative neoplasms occurrence.

Entities:  

Keywords:  Chronic lymphocytic leukemia; JAK2 V617F mutation; Myeloproliferative neoplasm

Year:  2013        PMID: 25332555      PMCID: PMC4192220          DOI: 10.1007/s12288-013-0281-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  15 in total

1.  Coexistence of essential thrombocythemia and chronic lymphocytic leukemia.

Authors:  N Y Gabrail; T W Martin
Journal:  Acta Haematol       Date:  1991       Impact factor: 2.195

2.  Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.

Authors:  Laurent Henry; Serge Carillo; Eric Jourdan; Anne Arnaud; Sophie Brun; Thierry Lavabre-Bertrand
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

3.  [Simultaneous presentation of chronic lymphocytic leukosis and essential thrombocythemia].

Authors:  F Marcos Sánchez; F Juárez Ucelay; C Lobato de Blas; M L Llanos del Ama; A Durán Pérez-Navarro
Journal:  An Med Interna       Date:  1995-11

4.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Authors:  Elisa Rumi; Francesco Passamonti; Chiara Elena; Daniela Pietra; Luca Arcaini; Cesare Astori; Silvia Zibellini; Emanuela Boveri; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

6.  JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).

Authors:  Srinivas Kodali; Chi Chen; Chenthilmurugan Rathnasabapathy; Jen Chin Wang
Journal:  Leuk Res       Date:  2009-07-22       Impact factor: 3.156

7.  Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi; Giovanna Masala; Elisabetta Antonioli; Maria Chiara Susini; Paola Guglielmelli; Lisa Pieri; Laura Maggi; Saverio Caini; Domenico Palli; Costanza Bogani; Vanessa Ponziani; Alessandro Pancrazzi; Francesco Annunziato; Alberto Bosi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-16       Impact factor: 4.254

8.  Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell?

Authors:  Piotr Tabaczewski; Sushani Nadesan; Seah H Lim
Journal:  Leuk Res       Date:  2008-10-11       Impact factor: 3.156

Review 9.  Coexistence of chronic lymphocytic leukemia and essential thrombocythemia.

Authors:  Tadeusz Robak; Halina Urbańska-Ryś; Joanna Góra-Tybor; Ewa Wawrzyniak; Anna Korycka; Jacek Bartkowiak; Radzisław Kordek; Aaron Polliack
Journal:  Leuk Lymphoma       Date:  2003-08

10.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.

Authors:  J L Binet; A Auquier; G Dighiero; C Chastang; H Piguet; J Goasguen; G Vaugier; G Potron; P Colona; F Oberling; M Thomas; G Tchernia; C Jacquillat; P Boivin; C Lesty; M T Duault; M Monconduit; S Belabbes; F Gremy
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

View more
  2 in total

1.  Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature.

Authors:  Filipa Mousinho; Paula Sousa E Santos; Ana P Azevedo; José Manuel Pereira; Raquel Lemos; Sónia Matos; João Faro Viana; Fernando Lima
Journal:  Mol Clin Oncol       Date:  2018-07-19

2.  Coexistence of Myeloid and Lymphoid Neoplasms: A Single-Center Experience.

Authors:  Anthi Bouchla; Thomas Thomopoulos; Sotirios Papageorgiou; Panagiotis Tsirigotis; Efthymia Bazani; Konstantinos Gkirkas; Diamantina Vasilatou; Eirini Glezou; Georgia Stavroulaki; Konstantinos Gkontopoulos; George Dimitriadis; Vasiliki Pappa
Journal:  Adv Hematol       Date:  2019-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.